MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

EOLS — Evolus, Inc. Common Stock

Nasdaq

Evolus, Inc. Common Stock

CompareBack to Screener
$7.14
-0.55(-7.15%)
O
7.72
H
7.72
L
6.91
V
2.07M
⏱️ End-of-day dataAs of Oct 2, 2026

Chart

About EOLS

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateFeb 8, 2018
Employees353
Stock ExchangeNasdaq
Ticker SymbolEOLS

Key Financial Statistics

Market Cap$471.60M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$3.86 - $9.31
52-Week Avg Volume1.07M
VWAP$7.23
Transactions20,191
Total Recorded Bars2,174 days